PE20091577A1 - Inhibidores de cinasa pim y metodos para su uso - Google Patents

Inhibidores de cinasa pim y metodos para su uso

Info

Publication number
PE20091577A1
PE20091577A1 PE2009000308A PE2009000308A PE20091577A1 PE 20091577 A1 PE20091577 A1 PE 20091577A1 PE 2009000308 A PE2009000308 A PE 2009000308A PE 2009000308 A PE2009000308 A PE 2009000308A PE 20091577 A1 PE20091577 A1 PE 20091577A1
Authority
PE
Peru
Prior art keywords
amino
methyl
pim kinase
methods
difluoro
Prior art date
Application number
PE2009000308A
Other languages
English (en)
Inventor
Matthew Burger
Jiong Lan
Mika Lindvall
Gisele Nishiguchi
Michelle Tetalman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41055566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091577(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091577A1 publication Critical patent/PE20091577A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TIAZOL DE FORMULA (I) DONDE R1 ES UN COMPUESTO DE FORMULA (a) O (b), DONDE R21 ES H O F; R22 ES H, Cl O F; R23 ES F, METILO, OH, ENTRE OTROS; R24 ES H U OH; X ES CH O N; R2a ES AMINO, METILO, CH2F, ENTRE OTROS; R2b ES H O METILO; R3 ES H, OH, OCH3, ENTRE OTROS; R4a ES AMINO, METILO, OH, F, ENTRE OTROS; R4b ES METILO, H O F. SON COMPUESTOS PREFERIDOS: (S)-5-AMINO-N-(4-(3-AMINO-PIPERIDIN-1-IL)-PIRIDIN-3-IL)-2-(2,6-DIFLUORO-FENIL)-TIAZOL-4-CARBOXAMIDA, N-(4-((3S,5R)-3-AMINO-5-ETIL-PIPERIDIN-1-IL)-PIRIDIN-3-IL)-2-(2,6-DIFLUORO-FENIL)-TIAZOL-4-CARBOXAMIDA, 5-AMINO-N-(4-((1R,3S)-3-AMINO-CICLOHEXIL)-PIRIDIN-3-IL)-2-(2,6-DIFLUORO-FENIL)-TIAZOL-4-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA CINASA PIM SIENDO UTILES EN EL TRATAMIENTO DE CANCER
PE2009000308A 2008-03-03 2009-02-27 Inhibidores de cinasa pim y metodos para su uso PE20091577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3335908P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
PE20091577A1 true PE20091577A1 (es) 2009-11-05

Family

ID=41055566

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000308A PE20091577A1 (es) 2008-03-03 2009-02-27 Inhibidores de cinasa pim y metodos para su uso

Country Status (21)

Country Link
EP (2) EP2262802B1 (es)
JP (1) JP5412448B2 (es)
KR (1) KR20100120709A (es)
CN (2) CN102015701B (es)
AR (1) AR070531A1 (es)
AU (1) AU2009221134B2 (es)
BR (1) BRPI0909102A2 (es)
CA (1) CA2717388A1 (es)
CL (1) CL2009000483A1 (es)
CO (1) CO6290687A2 (es)
EA (1) EA201001412A1 (es)
EC (1) ECSP10010447A (es)
ES (2) ES2562306T3 (es)
IL (1) IL207865A0 (es)
MA (1) MA32135B1 (es)
MX (1) MX2010009739A (es)
PE (1) PE20091577A1 (es)
TW (1) TW200942536A (es)
UY (1) UY31679A1 (es)
WO (1) WO2009109576A1 (es)
ZA (1) ZA201006128B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
US20080312259A1 (en) 2007-06-13 2008-12-18 Incyte Corporation SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
WO2010026124A1 (en) * 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
ES2487542T3 (es) 2009-05-22 2014-08-21 Incyte Corporation Derivados de N-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de cinasas Janus
CN106967070A (zh) 2009-05-22 2017-07-21 因塞特控股公司 作为jak抑制剂的化合物
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
JP5567136B2 (ja) * 2009-09-08 2014-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ４−置換ピリジン−３−イル−カルボキサミド化合物及び使用方法
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
ES2601004T3 (es) 2010-04-07 2017-02-13 F. Hoffmann-La Roche Ag Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso
CN103391936B (zh) * 2010-04-30 2016-04-27 国立大学法人东京大学 抗癌剂
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
EP2681197A1 (en) * 2011-03-04 2014-01-08 Novartis AG Tetrasubstituted cyclohexyl compounds as kinase inhibitors
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
CN102924444B (zh) * 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TWI570117B (zh) 2011-09-27 2017-02-11 赫孚孟拉羅股份公司 吡唑－４－基－雜環甲醯胺化合物及使用方法
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
PE20150194A1 (es) * 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
WO2014033631A1 (en) * 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
DK2900657T3 (da) 2012-09-26 2020-05-04 Hoffmann La Roche Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
NZ710079A (en) * 2013-01-15 2020-01-31 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
HUE057262T2 (hu) 2013-03-06 2022-04-28 Incyte Holdings Corp Eljárás és köztitermékek JAK inhibitor elõállítására
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
AR097431A1 (es) * 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AU2018335838B2 (en) * 2017-09-20 2022-06-30 Lead Discovery Center Gmbh Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CN112105608B (zh) 2018-01-30 2023-07-14 因赛特公司 制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
AU2019245420A1 (en) 2018-03-30 2020-11-12 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
KR20210146290A (ko) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US20090209522A1 (en) * 2005-06-28 2009-08-20 Graham Andrew Showell Heterocyclic Non-Peptide GNRH Antagonists
EP1945644A2 (en) * 2005-11-10 2008-07-23 Schering Corporation Imidazopyrazines as protein kinase inhibitors
KR20090004976A (ko) * 2006-04-19 2009-01-12 아스테라스 세이야쿠 가부시키가이샤 아졸카르복사미드 유도체
US9206142B2 (en) * 2006-10-31 2015-12-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
EP2078002B1 (en) * 2006-10-31 2013-08-28 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
AR063531A1 (es) * 2006-10-31 2009-01-28 Schering Corp Derivados de anilinopiperazina y composicion farmaceutica
EP2132177B1 (en) * 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
EP2596790B1 (en) 2015-12-09
EP2262802A1 (en) 2010-12-22
ES2562306T3 (es) 2016-03-03
WO2009109576A1 (en) 2009-09-11
CN102015701A (zh) 2011-04-13
JP5412448B2 (ja) 2014-02-12
EP2596790A1 (en) 2013-05-29
AR070531A1 (es) 2010-04-14
CN102015701B (zh) 2014-07-23
TW200942536A (en) 2009-10-16
AU2009221134B2 (en) 2012-02-23
CO6290687A2 (es) 2011-06-20
JP2011513363A (ja) 2011-04-28
ZA201006128B (en) 2011-10-26
ECSP10010447A (es) 2010-10-30
CL2009000483A1 (es) 2010-02-19
MX2010009739A (es) 2010-09-28
CA2717388A1 (en) 2009-09-11
IL207865A0 (en) 2010-12-30
EP2262802B1 (en) 2013-10-23
EA201001412A1 (ru) 2011-06-30
ES2443496T3 (es) 2014-02-19
UY31679A1 (es) 2009-09-30
CN104098559A (zh) 2014-10-15
KR20100120709A (ko) 2010-11-16
AU2009221134A1 (en) 2009-09-11
MA32135B1 (fr) 2011-03-01
BRPI0909102A2 (pt) 2019-01-15

Similar Documents

Publication Publication Date Title
PE20091577A1 (es) Inhibidores de cinasa pim y metodos para su uso
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
BRPI0409227C1 (pt) composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
BRPI0813044A2 (pt) "composto, composição fungicida e método para o controle do fungo fitopatogênico de culturas"
PE20071061A1 (es) Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ECSP10010556A (es) Piridinas y pirazinas como inhibidores de pi3k
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
PE20070179A1 (es) Derivados de purina como agonistas del receptor de adenosina a2
CY1112019T1 (el) Αγωνιστες υποδοχεων νιασινης, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι θεραπειας
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer

Legal Events

Date Code Title Description
FD Application declared void or lapsed